Abstract
Regulation of cellular iron homeostasis is crucial as both iron excess and deficiency cause hematological and neurodegenerative diseases. Here we show that mice lacking iron-regulatory protein 2 (Irp2), a regulator of cellular iron homeostasis, develop diabetes. Irp2 post-transcriptionally regulates the iron-uptake protein transferrin receptor 1 (TfR1) and the iron-storage protein ferritin, and dysregulation of these proteins due to Irp2 loss causes functional iron deficiency in $\beta$ cells. This impairs Fe-S cluster biosynthesis, reducing the function of Cdkal1, an Fe-S cluster enzyme that catalyzes methylthiolation of $t^6A37$ in $tRNA^{Lys}_{UUU}$ to $ms^2t^6A37$. As a consequence, lysine codons in proinsulin are misread and proinsulin processing is impaired, reducing insulin content and secretion. Iron normalizes $ms^2t^6A37$ and proinsulin lysine incorporation, restoring insulin content and secretion in $Irp2^{-/-}$ $\beta$ cells. These studies reveal a previously unidentified link between insulin processing and cellular iron deficiency that may have relevance to type 2 diabetes in humans.
Introduction: The Iron-Diabetes Link
While the medical community has long recognized that iron overload (as seen in hemochromatosis) increases the risk of type 2 diabetes (T2D), the impact of iron deficiency on insulin-producing $\beta$ cells has remained poorly understood. This study investigates how cellular iron homeostasis—the delicate balance of iron uptake and storage—directly affects the "translation fidelity" of proinsulin. The researchers focused on Iron Regulatory Protein 2 (Irp2), a master regulator of cellular iron, to determine why mice lacking this protein develop diabetes and whether the defect lies in insulin resistance or secretion failure.
Methodology: Probing Metabolic and Molecular Mechanisms
The authors employed a multi-disciplinary approach to distinguish between insulin resistance and secretion defects. They utilized global $Irp2^{-/-}$ mice for longitudinal physiological studies and performed metabolic clamps—the "gold standard" for measuring in vivo insulin action and secretion.
To explore the molecular basis, the team used CRISPR/Cas9 and shRNA to deplete Irp2 in rat insulinoma cells (INS-1). Advanced analytical techniques were key: ICP-MS measured metal content in isolated islets, while LC-MS/MS quantified specific tRNA modifications ($ms^2t^6A37$). Finally, metabolic labeling with radioactive isotopes ($^{14}C$-lysine and $^{3}H$-leucine) was used to measure the accuracy of amino acid incorporation into proinsulin.
Key Insights: Functional Iron Deficiency and the tRNA Connection
The study revealed that $Irp2^{-/-}$ $\beta$ cells suffer from "functional" iron deficiency. Even with normal systemic iron, the downregulation of the uptake protein TfR1 and upregulation of the storage protein Ferritin effectively "locks away" iron, starving the cell's internal machinery.
This deficiency impairs the biosynthesis of Iron-Sulfur (Fe-S) clusters, which are required for the enzyme Cdkal1. Cdkal1’s role is to add a methylthio group ($ms^2$) to a specific position on $tRNA^{Lys}_{UUU}$. Without this modification, the ribosome "stutters" or misreads lysine codons (AAA and AAG) in the proinsulin sequence. This leads to misfolded proinsulin that cannot be processed into active insulin, triggering endoplasmic reticulum stress. Crucially, the authors demonstrated that iron supplementation restored the tRNA modification and normalized insulin secretion in vitro, proving iron is the limiting factor.
Results: A Clear Diabetic Phenotype
Physiological monitoring confirmed that $Irp2^{-/-}$ mice develop significant glucose intolerance and elevated fasting glucose levels starting as early as 2.5 months of age.
Metabolic profiling using clamps and tolerance tests further characterized the defect. The $Irp2^{-/-}$ mice exhibited altered glucose infusion rates during clamps, which, combined with the observed glucose intolerance, points to a primary defect in endogenous insulin production.
Key experimental findings include:
- Secretion Deficit: Hyperglycemic clamps revealed a ~60% reduction in insulin secretion in $Irp2^{-/-}$ mice compared to wild-type controls.
- Islet Iron Loss: ICP-MS showed a 48% reduction in total iron content in $Irp2^{-/-}$ islets, while other metals like Zinc and Copper remained unchanged.
- Molecular Proof: LC-MS/MS confirmed a significant decrease in the $ms^2t^6A$ tRNA modification in Irp2-deficient cells, and metabolic labeling confirmed significantly reduced lysine incorporation into proinsulin.
Discussion: Limitations and Future Directions
While the study provides a robust molecular link between iron and insulin processing, it utilized global knockouts. Future work using $\beta$ cell-specific Irp2 knockouts would definitively rule out secondary effects from other tissues. Additionally, while CDKAL1 is a known risk gene for type 2 diabetes in humans, clinical studies are needed to confirm if iron deficiency in human patients leads to the same tRNA modification failures observed in the mouse model. The authors also noted reduced mitochondrial complex I activity, suggesting that energy production defects might contribute to the diabetic phenotype alongside the primary proinsulin processing error.
Summary updated